Codexis, Inc. (CDXS) Hit 1-Year High on May, 16

May 16, 2018 - By Carolyn Hewitt

Codexis, Inc. (NASDAQ:CDXS) Corporate Logo

During 2017 Q4 the big money sentiment decreased to 2.17. That’s change of 0.03, from 2017Q3’s 2.2. 3 investors sold all, 15 reduced holdings as Codexis, Inc. ratio is negative. 27 increased positions while 12 funds took positions. Funds hold 28.02 million shares thus 9.42% more from 2017Q3’s 25.60 million shares.
Barclays Public Lc reported 6,470 shs. Blair William And Company Il has invested 0.01% in Codexis, Inc. (NASDAQ:CDXS). Northern Tru Corp reported 429,439 shs. Tiaa Cref Investment Management Limited Liability Co holds 0% or 97,385 shs. Tower Research Capital Ltd Liability Com (Trc) has 0.01% invested in Codexis, Inc. (NASDAQ:CDXS). California State Teachers Retirement Systems accumulated 64,489 shs. 828,974 are held by Fmr Lc. Moreover, First Light Asset Mngmt Limited Liability Corporation has 1.84% invested in Codexis, Inc. (NASDAQ:CDXS). Burney invested in 20,000 shs. Thompson Davis & reported 18,535 shs. Bnp Paribas Arbitrage Sa owns 8,079 shs for 0% of their capital. Eam Invsts Lc accumulated 0.1% or 87,275 shs. Deutsche Fincl Bank Ag owns 107,089 shs. Bridgeway Mngmt holds 0% in Codexis, Inc. (NASDAQ:CDXS) or 14,500 shs. Ameritas Invest Partners has 2,608 shs for 0% of their capital.

Codexis, Inc. had 5 sales and 0 buys since March 21, 2018. This’s net activity of $1.19 million. $276,318 worth of Codexis, Inc. (NASDAQ:CDXS) shs were sold by BARUCH THOMAS R. KELLEY BERNARD J sold $124,683 worth of stock. Smith David V also sold $62,213 worth of Codexis, Inc. (NASDAQ:CDXS) shs. On Thursday, March 22 $259,828 worth of stock was sold by NICOLS JOHN J.

Codexis, Inc. (NASDAQ:CDXS) touched yearly high touching $14.11. Our price target is $15.24. Barchart.com reported it on May, 16. It has $751.49 million MC. At $15.24 stock price target, the company valuation changes by $60.12M more.

The stock increased 6.53% or $0.86 during the last trading session, hitting $14.11.Codexis, Inc. is uptrending after having risen 125.77% since May 16, 2017. CDXS has 492,171 volume or 17.42% up from normal. CDXS outperformed the S&P500 by 114.22%.

On August, 8. Investors expect Codexis, Inc. (NASDAQ:CDXS) to publish its quarterly earnings, as reported by RTT. Analysts have expectation on stock’s earnings per share of $-0.03. That’s up 76.92 % from last year’s $-0.13 earnings per share. After $-0.10 EPS report last quarter, Wall Street now predicts -70.00 % EPS growth of Codexis, Inc..

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

In total 2 analysts cover Codexis (NASDAQ:CDXS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CDXS) has 100% bullish analysts. With $1600 highest and $11.5 lowest PT, Codexis has $13.75 average PT or -2.55% below the current ($14.11) price. 2 are the (NASDAQ:CDXS)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Wednesday, May 16 the firm has “Buy” rating given by Stephens. On Monday, March 12 the company was maintained by H.C. Wainwright.

A couple more Codexis, Inc. (NASDAQ:CDXS) news were announced by: Globenewswire.com which released on May 10, 2018 “Codexis Reports First Quarter 2018 Financial Results”, also Globenewswire.com on May 03, 2018 announced “Codexis to Hold First Quarter 2018 Conference Call on May 10”, the next Nasdaq.com is “3 High-Growth Stocks That Are Just Getting Started” on May 12, 2018. Seekingalpha.com has article titled “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript”.

Codexis, Inc. discovers, develops, and sells protein catalysts.The firm is valued at $751.49 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening.Currently it has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.